Literature DB >> 11802251

Serum KL-6 levels in pediatric patients: reference values for children and levels in pneumonia, asthma, and measles patients.

Takehide Imai1, Masato Takase, Sachiyo Takeda, Toshiaki Kougo.   

Abstract

Serum KL-6 reflects alveolar damage and regeneration of type II pneumocytes, indicating disease activity in various interstitial lung diseases. We conducted a descriptive and observational multiple case-control study to determine the distribution of serum KL-6 levels in pediatric patients with or without respiratory diseases. Subjects were recruited from the patients of a teaching hospital in the suburb of Tokyo. A consecutive series of 401 children (0-16 years old) underwent blood sampling for many clinical reasons. They comprised the following four groups: pneumonia (n = 96), bronchial asthma (n = 101), measles (n = 102), and nonrespiratory diseases (n = 102) as a control group. Standard upper limits of serum KL-6 in a group of children with nonrespiratory disease were 250 U/mL, or half the adult level. No gender or age differences were observed. Elevated serum KL-6 concentrations were observed in severe pneumonia, acute exacerbations of asthma, and measles pneumonia. In the measles group, KL-6 values reflected the presence and severity of complicating pneumonia. We conclude that serum KL-6 levels exceeding 250 U/mL were rarely observed in children without respiratory diseases. In contrast, a substantial proportion of children with common respiratory diseases showed mild to moderate increases in serum KL-6 levels. Elevated serum KL-6 in these children may reflect the presence of alveolar damage, followed by regeneration of type II pneumocytes. However, in order to use serum KL-6 as a marker of interstitial lung diseases in children, a cutoff level should be determined separately. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11802251     DOI: 10.1002/ppul.10044

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  8 in total

1.  Usefulness of quantifying serum KL-6 levels in the follow-up of uveitic patients with sarcoidosis.

Authors:  Nobuyoshi Kitaichi; Toshihide Ariga; Satoru Kase; Kauzhiko Yoshida; Kenichi Namba; Shigeaki Ohno
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-08-23       Impact factor: 3.117

2.  Surfactant protein D is a biomarker of influenza-related pediatric lung injury.

Authors:  Arindam Chakrabarti; Allen Nguyen; Margaret M Newhams; Maikke B Ohlson; Xiaoying Yang; Sheila Ulufatu; Shannon Liu; Summer Park; Min Xu; Jenny Jiang; Wendy G Halpern; Veronica G Anania; Jacqueline M McBride; Carrie M Rosenberger; Adrienne G Randolph
Journal:  Pediatr Pulmonol       Date:  2021-12-07

3.  An exploratory study investigating biomarkers associated with autoimmune pulmonary alveolar proteinosis (aPAP).

Authors:  Ilaria Campo; Federica Meloni; Martina Gahlemann; Wiebke Sauter; Carina Ittrich; Corinna Schoelch; Bruce C Trapnell; Abhya Gupta
Journal:  Sci Rep       Date:  2022-05-24       Impact factor: 4.996

4.  Increase of KL-6 in sera of uveitis patients with sarcoidosis.

Authors:  Nobuyoshi Kitaichi; Satoshi Kotake; Hitoshi Shibuya; Yukiho Yamada; Hitoshi Chiba; Kenichi Namba; Shigeaki Ohno
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-10-11       Impact factor: 3.117

5.  Objectives, design and enrollment results from the Infant Susceptibility to Pulmonary Infections and Asthma Following RSV Exposure Study (INSPIRE).

Authors:  Emma K Larkin; Tebeb Gebretsadik; Martin L Moore; Larry J Anderson; William D Dupont; James D Chappell; Patricia A Minton; R Stokes Peebles; Paul E Moore; Robert S Valet; Donald H Arnold; Christian Rosas-Salazar; Suman R Das; Fernando P Polack; Tina V Hartert
Journal:  BMC Pulm Med       Date:  2015-04-30       Impact factor: 3.317

Review 6.  MUC1: The First Respiratory Mucin with an Anti-Inflammatory Function.

Authors:  Kosuke Kato; Erik P Lillehoj; Wenju Lu; Kwang Chul Kim
Journal:  J Clin Med       Date:  2017-11-29       Impact factor: 4.241

Review 7.  The Role of the Cell Surface Mucin MUC1 as a Barrier to Infection and Regulator of Inflammation.

Authors:  Poshmaal Dhar; Julie McAuley
Journal:  Front Cell Infect Microbiol       Date:  2019-04-24       Impact factor: 5.293

8.  Predicting the severity of acute bronchiolitis in infants: should we use a clinical score or a biomarker?

Authors:  Flore Amat; Cécile Henquell; Matthieu Verdan; Laurence Roszyk; Aurélien Mulliez; André Labbé
Journal:  J Med Virol       Date:  2013-12-27       Impact factor: 2.327

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.